The classic 2012 Cell review that became the standard reference for mTOR signaling. Comprehensive yet readable synthesis of how mTOR integrates environmental cues to control growth, and how its deregulation drives cancer, obesity, diabetes and neurodegeneration. A perfect companion to the newer 2020 review.
| Evidence tier | D Mechanistic / in vitro / review |
| Study type | Narrative Review |
| Model system | Review (comprehensive) |
| Journal | Cell |
| Year | 2012 |
| Peer reviewed | Yes |
| Source | DOI 10.1016/j.cell.2012.03.017 · PMID 22500797 · Free full text (PMC3331679) |
The mechanistic target of rapamycin (mTOR) signaling pathway senses and integrates a variety of environmental cues to regulate organismal growth and homeostasis. The pathway regulates many major cellular processes and is implicated in an increasing number of pathological conditions, including cancer, obesity, type 2 diabetes, and neurodegeneration. Here, we review recent advances in our understanding of the mTOR pathway and its role in health, disease, and aging. We further discuss pharmacological approaches to treat human pathologies linked to mTOR deregulation.
| Intervention | Not applicable (review) |
| Target | mTORC1 / mTORC2 |
| Model | Review |
| Effect | Comprehensive review of mTOR signaling in growth control and disease (cancer, obesity, diabetes, neurodegeneration) |